Get started
Work

Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1 - PDF file 37K, Most Common (incidence >10%) Grade 3/4 Toxicities per Dose Group
DOI: 10.1158/1078-0432.22445375.v1
Authors: Evanthia Galanis, S. Keith Anderson, Jackie M. Lafky, Joon H. Uhm, Caterina Giannini, Shaji K. Kumar, Teresa K. Kimlinger, Donald W. Northfelt, Patrick J. Flynn, Kurt A. Jaeckle, Timothy J. Kaufmann, Jan C. Buckner
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361902977
Cites:
Cited by:
Related to: 10